新的抗癌药物4-利基胺-5-碳酸盐向Hsp90的目标
Cinzia Bordoni1,2, Tia Z Elstow1, Andrea Brancale1,3
1School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, UK.
Chemical biology & drug design
|December 15, 2025
概括
研究人员开发了新的4-aryldihydropyrimidinone-5-carboxylate衍生物作为热冲击蛋白90 (Hsp90) 抑制剂用于癌症治疗. 化合物5d显示出强大的抗癌活性和Hsp90抑制,使其成为进一步药物开发的有希望的候选者.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 分子药理学分子药理学
背景情况:
- 热冲击蛋白90 (Hsp90) 在癌症中过度表达,与预后不佳相关,并促进瘤进展.
- 现有的Hsp90抑制剂在临床上取得了有限的成功,需要开发新的化学支架.
- 向Hsp90是癌症治疗中的一个有希望的策略,但需要新的抑制剂.
研究的目的:
- 设计和合成新型的4-aryldihydropyrimidinone-5-carboxylate衍生物作为潜在的Hsp90抑制剂.
- 在人类乳腺癌模型中评估这些化合物的结构活性关系 (SAR).
- 为了确定有前途的命中化合物用于进一步的临床前开发.
主要方法:
- 虚拟选发现了一种模仿凝胺氨酸与Hsp90 ATP位点结合的打击化合物.
- 合成了一系列替代的4-aryldihydropyrimidinone-5-carboxylate衍生物 (5a-n) 的合成.
- 在乳腺癌细胞系中对Hsp90抑制,细胞生长抑制,殖民地形成和早期ADME剖析的评估.
主要成果:
- 化合物5d在乳腺癌细胞系中表现出强大的殖民地形成抑制作用.
- 化合物5d有效抑制了Hsp90的活动.
- 早期的ADME分析表明5d化合物的代谢稳定性和可溶性适度,没有hERG通道抑制.
结论:
- 化合物5d是一种有前途的热门化合物,具有强大的抗癌活性和Hsp90抑制作用.
- 4 - 二胺-5 - 碳酸盐基架代表了开发新型Hsp90抑制剂的可行起点.
- 对化合物5d的进一步优化对于潜在的癌症治疗应用是有必要的.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
567
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
567
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
518
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
518
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


